Company profile
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral
- CEO
- —
- Headquarters
- Solana Beach, CA, United States
- Employees
- 14
- IPO date
- Aug 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology